RNAC

SEC source: 0001453687-25-000018 · wk-form4_1736198370.xml · nonDerivative · entry 1

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,133

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029.

SEC source: 0001453687-25-000017 · wk-form4_1736198360.xml · derivative · entry 8

Singer Michael · CIK 0002000122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,800

Underlying: Common Stock · 7,800 shares

Expires 2035-01-01

SEC source: 0001453687-25-000017 · wk-form4_1736198360.xml · nonDerivative · entry 1

Singer Michael · CIK 0002000122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,533

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026.

SEC source: 0001453687-24-000149 · wk-form4_1735593112.xml · derivative · entry 2

English Emily · CIK 0002019791 · SVP, Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,369

Underlying: Common Stock · 7,650 shares

Expires 2031-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of Common Stock in connection with the merger.

F1 · derivative.exercise_date: These options are currently exercisable for an additional 35,114 shares of Common Stock and become exercisable for a further 14,255 shares of Common Stock on March 22, 2025.

SEC source: 0001453687-24-000149 · wk-form4_1735593112.xml · nonDerivative · entry 1

English Emily · CIK 0002019791 · SVP, Head of Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,923

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000151 · wk-form4_1735593244.xml · nonDerivative · entry 1

Singer Michael · CIK 0002000122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,933

SEC source: 0001453687-24-000147 · wk-form4_1734992437.xml · nonDerivative · entry 5

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,507,895

F5 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.98 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000147 · wk-form4_1734992437.xml · nonDerivative · entry 4

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,502,714

F4 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.73 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000147 · wk-form4_1734992437.xml · nonDerivative · entry 3

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,480,914

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.82 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000147 · wk-form4_1734992437.xml · nonDerivative · entry 2

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,477,538

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.82 to $18.8125. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000147 · wk-form4_1734992437.xml · nonDerivative · entry 1

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,467,009

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.81 to $17.7912. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · derivative · entry 7

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,099

Underlying: Common Stock · 2,901 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F4 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 5.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · nonDerivative · entry 5

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.00 to $24.78. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · nonDerivative · entry 4

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,934

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · derivative · entry 6

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,000

Underlying: Common Stock · 10,763 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F4 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 5.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · nonDerivative · entry 3

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $25.58 to $26.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · nonDerivative · entry 2

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,572

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.58 to $25.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · nonDerivative · entry 1

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,796

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · derivative · entry 10

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,763

Underlying: Common Stock · 32,789 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F3 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 4.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 7

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.50 to $17.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 6

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,822

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · derivative · entry 9

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,552

Underlying: Common Stock · 5,700 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F3 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 4.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 5

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 4

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,133

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.01 to $17.98. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 3

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,733

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000138 · wk-form4_1732233005.xml · derivative · entry 2

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,432

Underlying: Common Stock · 14,000 shares

Expires 2033-01-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F1 · derivative.exercise_date: The option is currently exercisable for 123,235 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025.

SEC source: 0001453687-24-000138 · wk-form4_1732233005.xml · nonDerivative · entry 1

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,940

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · derivative · entry 8

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,252

Underlying: Common Stock · 200 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F3 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 4.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 2

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 1

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,233

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000139 · wk-form4_1732233090.xml · nonDerivative · entry 1

Singer Michael · CIK 0002000122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,933

SEC source: 0001453687-24-000134 · wk-form4_1731976543.xml · nonDerivative · entry 5

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,455,706

F5 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.32 to $18.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000134 · wk-form4_1731976543.xml · nonDerivative · entry 4

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,435,525

F4 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.32 to $18.315. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · derivative · entry 11

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,452

Underlying: Common Stock · 34,400 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F6 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 7.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · nonDerivative · entry 8

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.50 to $18.69. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · nonDerivative · entry 7

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,761

F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.50 to $18.49. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · nonDerivative · entry 6

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,433

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000134 · wk-form4_1731976543.xml · nonDerivative · entry 3

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,397,411

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.61 to $17.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · derivative · entry 10

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,852

Underlying: Common Stock · 22,068 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F6 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 7.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · nonDerivative · entry 5

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · nonDerivative · entry 4

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,101

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000130 · wk-form4_1731976078.xml · derivative · entry 6

Miljkovic Milos · CIK 0002000282 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,528

Underlying: Common Stock · 20,000 shares

Expires 2031-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F3 · derivative.exercise_date: The option is currently exercisable for 64,146 shares of Common Stock and becomes exercisable for the remaining 21,382 shares of Common Stock on September 13, 2025.

SEC source: 0001453687-24-000130 · wk-form4_1731976078.xml · nonDerivative · entry 4

Miljkovic Milos · CIK 0002000282 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,273

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.465. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000130 · wk-form4_1731976078.xml · nonDerivative · entry 3

Miljkovic Milos · CIK 0002000282 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,273

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000128 · wk-form4_1731975821.xml · derivative · entry 7

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,432

Underlying: Common Stock · 16,065 shares

Expires 2033-01-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F4 · derivative.exercise_date: The option is currently exercisable for 123,235 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025.

SEC source: 0001453687-24-000128 · wk-form4_1731975821.xml · nonDerivative · entry 5

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,940

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.24. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000128 · wk-form4_1731975821.xml · nonDerivative · entry 4

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,005

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000134 · wk-form4_1731976543.xml · nonDerivative · entry 2

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,120,165

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.71 to $17.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000134 · wk-form4_1731976543.xml · nonDerivative · entry 1

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,097,923

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $15.65 to $16.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · derivative · entry 9

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,920

Underlying: Common Stock · 25,900 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F6 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 7.